Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 2/20 | 1.00 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.68 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.68 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642230 | 0.93 | ADRA1D (0.86) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL11626419 | 0.93 | ADRA1A (0.86) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL7067872 | 0.93 | ADRA1D (0.86) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL11617045 | 0.86 | ADRA1D (0.76) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL11938908 | 0.85 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL5179385 | 0.85 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL6224848 | 0.85 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL11631801 | 0.85 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL11631806 | 0.85 | ADRA1D (0.74) | ADRA1DADRA1AADRA1BCARM1PRMT6 | |
| SCHEMBL11424202 | 0.84 | ADRA1A (0.72) | ADRA1DADRA1AADRA1BMCHR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0663014-B1 | DNA ENCODING HUMAN ALPHA 1 ADRENERGIC RECEPTORS AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6602888-B2 | Binds to a human alpha 1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human alpha 1A adrenergic receptor | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20030113771-A1 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030113772-A1 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-19 | — | — | US | disclosed |
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6448011-B1 | ISOLATED NUCLEIC ACID, VECTORS, TRANSFORMED MAMMALIAN CELLS AND NON-HUMAN TRANSGENIC ANIMALS THAT ENCODE AND EXPRESS NORMAL OR MUTANT ADRENERGIC RECEPTOR GENES. | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | H. LUNDBECK A/S (DK) | 2002-03-14 | — | — | US | disclosed |
| EP-1063292-A2 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | Synaptic Pharmaceutical Corporation (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1063291-A2 | DNA encoding human alpha 1 adrenergic receptors and uses thereof | Synaptic Pharmaceutical Corporation (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6156518-A | Methods of using DNA encoding human alpha 1 adrenergic receptors | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-05 | — | — | US | disclosed |
| US-5578611-A | ANTITUMOR AGENTS AND PROSTATE TUMOR DETECTION BY BINDING HUMAN ALPHA-ADRENERGIC RECEPTOR AND HISTAMINE H1 RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| US-5508306-A | USED FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, LOWERING INTRAOCULAR PRESSURE AND INHIBITING CHOLESTEROL SYNTHESIS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1995028157-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-10-26 | — | — | WO | disclosed |
| EP-0667769-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-08-23 | — | — | EP | disclosed |
| EP-0663014-A1 | DNA ENCODING HUMAN ALPHA 1 ADRENERGIC RECEPTORS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1995007075-A9 | NOVEL AROMATIC AMINE DERIVATIVES | — | 1995-04-27 | — | — | WO | disclosed |
| US-5403847-A | Administering a therapeutic amount of a compound which binds to a human alpha 1c adrenergic receptor; FDA Orange book listed patent for silodosin | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-04-04 | — | — | US | disclosed |
| WO-1995007075-A1 | NOVEL AROMATIC AMINE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1995-03-16 | — | — | WO | disclosed |
| WO-1994010989-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994008040-A1 | DNA ENCODING HUMAN ALPHA 1 ADRENERGIC RECEPTORS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022900-A1 | Compositions comprising alpha-1C specific compounds | ADRB1, ADRA1B, ADRA1A | ADRA1D 4/4885ADRA1A 3/4885ADRA1B 2/4885 |
| US-20020032219-A1 | USE OF ALPHA-1C SPECIFIC COMPOUNDS TO TREAT BENIGN PROSTATIC HYPERPLASIA | ADRB1, ADRA1B, ADRA1A | ADRA1D 4/4885ADRA1A 3/4885ADRA1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.